Interleukin 2 in cell-mediated immune responses

Journal of Supramolecular Structure
V PaetkauK C Lee

Abstract

The lymphokine Interleukin 2(IL2) restores T cell responses in a number of in vitro systems where immunogenicity has been compromised. UV irradiation of the stimulating allogeneic cells in a mixed leukocyte culture eliminates the production of cytotoxic T lymphocytes and greatly reduces the DNA synthesis response. IL2 restores both parameters. UV-irradiated stimulators are also unable to induce the normal production of IL2 which is observed in a mixed leukocyte culture. The cytotoxic activity of allogeneically stimulated thymocytes is almost completely lost within 24 hours after removal of IL2 at 5 days, indicating that the lymphokine is continuously required to maintain CTL. Thymocytes in 4-day cultures do not adsorb IL2 unless they are simultaneously activated with a mitogen. Finally, IL2 does not adequately restore a secondary response to the purified protein derivative of tuberculin (PPD) in adherent-cell-depleted cultures, indicating that macrophages, in addition to being required for IL2 production, have other functions. These probably include the presentation of soluble antigens to responding cells.

References

Jan 1, 1979·Journal of Immunological Methods·K C LeeM Wong
Aug 1, 1979·European Journal of Immunology·A CoutinhoJ Andersson
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·D W TalmageK J Lafferty
Oct 1, 1978·The Journal of Experimental Medicine·S GillisK A Smith
Aug 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·A G FarrE R Unanue
Feb 14, 1980·Nature·E L LarssonA Coutinho
Jan 1, 1980·Immunological Reviews·V PaetkauB Caplan

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.